Molecular imaging developer Positron of Fishers, IN, said it plans to explore additional market opportunities for its Attrius PET scanner.
The decision comes in the wake of the U.S. Food and Drug Administration's (FDA) conditional approval of Eli Lilly's PET imaging agent Amyvid (florbetapir) on January 20 for detecting beta amyloid plaque deposits that could lead to Alzheimer's disease.
The Attrius PET system is applicable for brain imaging due to its small footprint, among other factors, Positron said.
